SCHEMBL4967737

SCHEMBL4967737

O=C(Nc1cccc(C(F)(F)F)c1)c1cc(F)cnc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 2/20 0.58
SLC2A1 P11166 1/20 0.58
P2RX4 Q99571 1/20 0.58
P2RX7 Q99572 1/20 0.58
TMPRSS4 Q9NRS4 1/20 0.58
RXFP1 Q9HBX9 5/20 0.56
GAA P10253 1/20 0.56
AHR P35869 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PTGS1 P23219 1/20 0.55
EPAS1 Q99814 2/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KCNQ3 O43525 1/20 0.53
KCNQ2 O43526 1/20 0.53
KCNE1 P15382 1/20 0.53
KCNQ1 P51787 1/20 0.53
KCNQ5 Q9NR82 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28789750 0.90 P2RX1 (0.60) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL29732883 0.90 P2RX1 (0.60) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL4966684 0.86 NFKB1 (0.58) P2RX1P2RX4P2RX7TMPRSS4PTGS1
SCHEMBL3110003 0.82 KMT2A (0.65) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL4969158 0.81 KCNQ3 (0.47) TMPRSS4KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL4968696 0.81 KCNQ3 (0.56) TMPRSS4KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL4969767 0.81 GRM4 (0.59) TMPRSS4GAAMAPTKMT2AMEN1
SCHEMBL31171402 0.80 P2RX1 (0.57) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL4969220 0.79 NFKB1 (0.47) P2RX1P2RX4P2RX7TMPRSS4KCNQ3
SCHEMBL4969026 0.79 PTGS1 (0.54) GAAPTGS1EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP disclosed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS P2RX1 1373/4885SLC2A1 265/4885P2RX4 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.